A Life Sciences Industry Professional with over 35 years sales & marketing, and business development experience in pharmaceuticals, and over 20 years in biotech corporate development. Historically specialising in assisting start-up companies - from development, evaluation & in-licensing of new technologies, through initiation of strategic alliances with multi-national corporate partners, to leading sales & marketing teams on commercial stage products. Has led the closing of over 35 financing/alliance/licensing deals. Extensive contacts nationally and worldwide with elite senior corporate executives, government officials, lobbyists, and academia. Currently actively involved with founding, financing and helping to operate start-ups, with a broad focus in the sustainability sector.

Agritech Innovations Inc. is a Canadian agricultural input and crop protection company. It is privately held, incorporated in the province of British Columbia.Agritech Innovations’ strategic vision and mission is to become a leading provider of aggregator agriculture technology for environmentally friendly/sustainable farm input and protection products – both domestically and globally. Our ultimate goals are to improve & maximize farmers’ yields, improve plant health, and prevent fertilizer and insecticide pollution in both an environmentally friendly/sustainable and cost-effective way.Agritech is working closely with our California-based supplier/partner, Green Wave Products LLC, to bring their sustainable/environmentally friendly AgriPower™ fertilizers and Agri X Shield™ pesticide, miticide & fungicide to Canada & the world. As agents for GWP we have also helped Green Wave establish partnerships to take these revolutionary products to the U.K., France, Germany, the Netherlands, Belgium, Russia, Sri Lanka, India, Africa, the Caribbbean, South America and Mauritius.

As a Partner in DriveOn Protection, we are the exclusive Canadian Distributor for eco-friendly, economic, and sustainable product line from PermaSeal Global, including:PermaSeal™, the only environmentally friendly, Nano-Technology Tire Sealant with a global insurance carrier backed Manufacturers Warranty, permanent fix solution. PermaSeal is: o completely green, eco-friendly and water soluble o a preventive, and permanent fix o easy to install o applicable to passenger vehicles to heavy truck formulations o an enabler of No Flats…Guaranteed!PermaFuel® Fuel Additive delivers cost and environmental efficiencies by reducing fuel consumption and minimizing carbon output. PermaFuel is a unique fuel “catalyst” that dramatically improves: o fuel economy o fuel/engine performance o the environment by reduces carbon and emissions o diesel regeneration cycle by reducing their required frequency by 50% o Diesel Exhaust Fluid efficiency, thereby reducing required volume by 50%DriveOn Protection is also aligned with Canadian Truck Warranty (CTW), who are: o the only Canadian commercial heavy/mid-size truck/trailer/stand alone Reefer/bus/motor coach warranty provider; o providing fully licensed and insured (Amtrust) warranty programs o providing New, Pre-owned Truck and Trailer coverage up to $80,000 o providing warranties for solar powered Reefer conversions o providing warranties for solar powered golf carts conversions o providing warranties for Electric Vehicle (EV) programs

There once was a wee Scottish lad by the name of Graeme Macaloney who found a summer job bottling whisky and fell in love with Uisge Beatha, the ‘water of life’. He dedicated his heart to finding a way to make whisky for a living, though circumstance would find a way of sidetracking his dreams.Knowing he couldn’t create a world-class brewery and distillery on his own, Graeme assembled a skilled team of experts: the legendary Dr Jim Swan, the foremost whisky maturation expert in Scotland, and Master Distiller Mike Nicolson, who had worked in over 18 renowned Scottish whisky distilleries.The result has been a multitude of National & International beer and whisky awards!

At a time when we are demanding more from the things we invest in, why is it that we expect so little from the item we spend more money on and the most time in; our shelters? Nouvel Housing is Canada's exclusive provider of California's Binishell homes.Nouvel & Binishell draw inspiration from nature to bring a cohesive and innovative ‘out of the box' approach to construction and design. In so doing, we bring a new level of efficiency and resiliency to construction whilst adding a level of objectivity to design.Our approach and philosophy is rooted in nature: in how forces work within materials; how weight is transferred; and how structural systems gain efficiency. They are rooted in how heat is transferred versus how it is contained. They are rooted in more closely emulating how nature works. The process of the exploration of design with equal consideration to construction methodology, remembering that light is to architecture as sound is to music. While Binishells has clients such as Robert Downie Jr., (Iron Man), our goal is to provide affordable, einvironmentally friendly, earthquake & wildfire safe housing for everyone.

Sernova is a clinical stage regenerative medicine company focused on developing & commercializing its platform technologies based on the Company’s proprietary Cell Pouch System (CPS), micro-encapsulation, genetic engineering (local anti-rejection control) & therapeutic cells. Sernova has licensed/partnered technologies from multiple world-class corporate & academic institutions related to the development of islets (xenogeniec & human) and stem cells into glucose-responsive therapeutic cells for the treatment of T-1 diabetes. The CPS is a novel, subcutaneously implantable & scalable business card-sized medical device scaffold, forming a natural environment in the body for the housing & long-term survival & function of therapeutic cells. As the CPS is fully integrated into the body’s vascular system, these therapeutic cells release necessary proteins, hormones or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs according to the body’s specific therapeutic needs when required – as per normal physiologic functioning. The CPS is ideally suited for allogeneic, autologous, stem cell & xenogeneic applications.Sernova's current FDA approved Ph. I/II Chicago-based trial goals for the CPS include clinically validating the ability to treat T-1 diabetes via donor islet transplantation to create endogenous production of insulin, somatostatin, and glucagon to control blood glucose without any external monitoring or insulin/hormonal sources. The primary long-term goal for the CPS is to provide a "cure" for T-1 diabetes by providing a safe, fully vascularized environment for sources of unlimited insulin-secreting cells. Pre-clinical work on the CPS is also underway to treat Hemophilia A with controlled endogenous production of Factor VIII via Blood Origin Endothelial Derived Cells, as well as endogenous production of thyroid hormone for benign thyroid diseases. Pipeline applications include Parkinson's Disease.

EPM is a global leader in the research & development of patentable stable cannabinoid acid molecules. EPM was founded to address two critical but largely unknown needs: unlocking the potential of cannabinoid acids; and bridging the gap between the pharmaceutical and cannabis industries. EPM is at the forefront of conducting ground-breaking research into cannabinoid acid molecules for use in the development of medicines.

Eternity Healthcare was a healthcare company developing technologies in medical devices and diagnostics. Our most advanced product was a needle-free injection system known as Comfort-in. Our products were sold to healthcare professionals, for use in physicians' offices, pharmacies, and also to consumers (end-users) directly.

- responsible for licensing & acquisition activities in Healthcare Services/eHealth Solutions, Oncology & Diabetes (therapeutics and diagnostics), Natural Health Products and Medical Devices.- member, SANOFI Global Oncology Business Opportunities task force.- member, SANOFI Global PIC-STAR (CHF remote patient monitoring) team.- member, SANOFI global diabetes licensing & acquisition group.- responsible for contract negotiations and renewals for SANOFI Canada’s contract manufacturing and distribution operations.

As C.F.O., Secretary and Director of Capital Pool Company (CPC) / Special Purpose Acquisition Company (SPAC) Karma Capital Corp., I was instrumental in the eventual completion of Karma's "Qualifying Transaction" which was the amalgamation with, and subsequent I.P.O. of Biosign Technologies Inc., (TSX-V: BIO) a Toronto-based remote patient monitoring & diagnostics company.

As a Director at Nucleus, I was responsible for the continuous disclosure requirements of this Capital Pool Company (CPC) / Special Purpose Acquisition Company (SPAC); the due diligence of potential Qualifying Transactions; and the eventual amalgamation with two other CPC's/SPAC's, Brightwave and Stratos, to form the first "Super CPC/SPAC", SNB Capital Corp. SNB completed its Qualifying Transaction via the Reverse Take-Over and subsequent IPO of Protox Therapeutics, a Vancouver-based cancer therapeutics development company, which subsequently moved to San Diego and became Sophiris Bio Inc. (NASDAQ: SPHS)

MLN Ltd. was an Oxford University spin-off drug discovery company. We had a glycobiology-based cancer research programme. Using our proprietary Phytoquest process, MNL was able to regularly isolate novel imino sugars of low molecular weight. The use of imino sugars provided a new approach for cancer therapy research. MNL had developed a series of compounds that increased both dendritic cell and macrophage IL-12 production. MNL also actively marketed a naturally sourced small molecule compound library for discovery & chemistry teams of biotech & Big Pharma companies, and academic institutions such as Oxford, Harvard, U.C.S.D. & Kyoto University.

• Recruited, developed and led oncology/transplant field force.• Developed and supervised successful implementation of marketing strategies and tactics in the field, resulting in >9-fold sales increase.• 100% protocol & provincial funding attainment success rate as Market Access Team Leader.• Established & managed strategic partnerships between basic/clinical research communities in oncology/organ transplantation and Novartis Pharma.

Prior to Ciba-Geigy's merger with Sandoz in 1996 to create Novartis, roles at Ciba-Geigy included:Oncology Product Specialist - Western CanadaKey Accounts, Hospital Representative - VancouverSales Training Manager; Product Manager - TorontoPrimary Care & Specialist Representative - Kelowna